All In Biotech

Drug Trial Radar · NCT01225731

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Study P05495)

Last checked: Nov 20, 2026Latest source record: Feb 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 355 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

355

Actual

Start

Oct 25, 2010

Primary completion

Nov 4, 2011

Study completion Oct 24, 2012

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 21, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a response-driven study of tildrakuzumab for the treatment of moderate to severe chronic plaque psoriasis. The primary study hypothesis is that one or more doses of tildrakizumab will be superior to placebo for the treatment of psoriasis.

Conditions

  • Psoriasis

Interventions

  • tildrakizumabBiological

    SC administration of tildrakizumab at assigned dose

  • PlaceboDrug

    SC administration of Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Psoriasis Area and Severity Index (PASI)75 Response at Week 16Time frame: Week 16
  2. Number of Participants Experiencing Adverse EventsTime frame: Up to 72 weeks
  3. Number of Particpants Discontinuing Study Treatment Due to Adverse EventsTime frame: Up to 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.